Schisandra: The Definitive Guide

What is schisandra?

Schisandra usually refers to the dried fruit of Schisandra chinensis, also called Chinese magnoliavine or wu wei zi. Its fruit contains dibenzocyclooctadiene lignans, including schisandrin compounds. Fruit, seed, whole-plant material and isolated lignans are not interchangeable.

Species is central to safety. Schisandra sphenanthera supplies the Wuzhi products studied with tacrolimus. Those human interaction findings should not be silently relabelled as a trial of S. chinensis, but they show why the exact species and medicines must be reviewed. [5], [6]

“Adaptogen” is a traditional and commercial category. It does not prove that schisandra normalizes stress hormones, protects the liver or improves energy in every user.

Typical Schisandra Protocols

There is no RDA, AI, UL or universal clinical dose. A dried-fruit equivalent, a named extract and a capsule count are different units. Do not use the Canadian licensing range to reconstruct BMO-30, the 1 g extract, or a Wuzhi product. [1]

Titration

The selected efficacy trials assigned fixed daily totals. They do not establish a general step-up method.

Timing

The available abstracts do not establish a universally superior relationship to meals or exercise.

Duration

Highlighted S. chinensis trials lasted six to twelve weeks. Long-term continuous use remains poorly characterized.

Stopping

No evidence-based taper is established. Medicine levels may need clinical monitoring when an interacting product is added or removed.

What is schisandra commonly used for?

People use schisandra for fatigue, stress, exercise, menopausal symptoms, cognition and “liver support.” Canadian cognitive-function product conditions include S. chinensis dried fruit as an adaptogen ingredient at defined dried-fruit-equivalent amounts. That licensing pathway does not prove disease treatment or transfer an outcome from one extract to another. [1]

Human research is much smaller than the laboratory literature. The clearest standalone S. chinensis studies concern menopausal symptom scores and muscle strength. Liver research often uses combination products or laboratory endpoints, while many stress and cognition claims rely on multi-herb formulas.

Which form and label details matter?

Read the label in this order:

1. Species: S. chinensis or S. sphenanthera.
2. Plant part: fruit, seed or another material.
3. Preparation: whole dried fruit, powder, aqueous or ethanolic extract.
4. Extract identity: named products such as BMO-30 or Wuzhi are not reproduced by mass alone.
5. Marker statement: record total lignans or named schisandrins and the assay basis.
6. Other ingredients: sesamin and other adaptogens prevent attribution to schisandra alone.

Common names including wu wei zi, nan-wuweizi and “five-flavour berry” may obscure species. Use the Latin binomial for evidence matching.

What does the human evidence show?

Menopausal symptoms

Forty-one women were randomized to BMO-30 or placebo; 36 completed. The primary comparison was change in the Kupperman Index to week 12 after six weeks of treatment. The active group had a lower total score over group and time, with reported signals for hot flushes, sweating and palpitations. The sample was tiny, the result belongs to BMO-30, and a symptom score does not establish broad endocrine effects. [2]

Strength and muscle mass

In 54 adults over 50 with relatively low muscle mass, 1 g/day of S. chinensis extract plus a walking program increased right and left knee-extension strength more than placebo plus walking over 12 weeks. Muscle mass, inflammatory and antioxidant markers, and quality of life did not differ. One small trial does not establish prevention or treatment of sarcopenia. [3]

Liver markers

A randomized trial studied 260 mg schisandra fruit extract combined with 10 mg sesamin in people with elevated liver enzymes. Because both ingredients were administered together, the enzyme changes cannot identify schisandra's independent contribution. Lower ALT or AST is a surrogate result and not proof of treating fatty liver, hepatitis or drug injury. [7]

Tacrolimus interaction and species boundary

Twelve healthy men took S. sphenanthera extract for 13 days. Exposure to a 2 mg tacrolimus dose rose substantially: average AUC increased 164% and peak concentration 227%. Transplant-patient studies also report higher tacrolimus concentrations. These studies involve another Schisandra species, but they establish that the common-name family can create clinically important pharmacokinetic interactions. Never use such an interaction to deliberately change tacrolimus exposure outside transplant care. [5], [6]

What remains uncertain

• independent replication of the menopause and strength results;
• effects on diagnosed fatigue, cognitive, liver or muscle disorders;
• long-term safety and reproductive safety;
• equivalence among species, batches, whole fruit and standardized extracts;
• interaction magnitude for S. chinensis products and different medicines;
• whether liver-enzyme changes correspond to better clinical outcomes.

How might it work?

Schisandra lignans have been studied for effects on drug-metabolizing enzymes, P-glycoprotein transport, oxidative signaling and inflammatory pathways. Much of the efficacy work is preclinical. The human tacrolimus findings demonstrate a pharmacokinetic effect for S. sphenanthera; they do not prove a beneficial “detox” mechanism. [5], [6]

Proposed antioxidant or stress-response pathways cannot be converted into a claim that an oral product protects the liver, brain or muscles. Human exposure, species and preparation must match.

What are the risks and interactions?

Schisandra has limited systematic human safety data. Small trials report few serious events, but that cannot exclude uncommon harm. Sleepiness and cold extremities occurred in both arms of one small trial summarized by MSK. Digestive or allergic symptoms are also plausible with botanical products. [4]

Interaction risk is the main practical concern. MSK flags CYP1A2, CYP3A4, CYP3A5 and P-glycoprotein substrates. The clinical relevance varies by species and product, but tacrolimus has direct human evidence. Medicines with a narrow therapeutic range require pharmacist or prescriber review before starting or stopping schisandra. [4], [5], [6]

Pregnancy, breastfeeding and pediatric safety are not established. Avoid using liver-enzyme changes to mask injury or delay assessment. Disclose schisandra before surgery and before medication-level testing.

Seek prompt care for severe allergy, jaundice, dark urine, persistent vomiting, fainting, severe tremor or confusion, or symptoms of medicine toxicity.

Legal status in the United States and Canada

In the United States, schisandra is commonly sold as a dietary supplement. FDA does not approve supplements for safety and effectiveness before sale, and a supplement cannot legally claim to treat menopause, sarcopenia or liver disease. [8]

In Canada, natural health products require a product licence and NPN. The cognitive-function product monograph includes S. chinensis dried fruit under defined conditions. A licensed product remains distinct from S. sphenanthera and from the named trial extracts. [1]

What should you monitor?

Record the Latin species, plant part, extract, ratio, lignan statement, lot, other ingredients and schedule. For a symptom goal, select one repeatable measure and a review date. For strength, use the same safe functional task rather than interpreting day-to-day sensation.

If a medicine-level interaction is possible, monitoring belongs to the prescriber. An app cannot interpret tacrolimus concentrations, liver tests or dose changes.

What happens when you stop?

The selected efficacy trials do not establish withdrawal or tapering. Starting or stopping a product that changes medicine transport could alter drug exposure, so follow the prescriber's monitoring plan rather than changing medicine doses yourself.

How should it be stored?

Follow the product label. Keep it closed, dry, away from heat and children, and discard changed or expired products. General advice cannot establish stability for every powder, tincture or extract.

How does schisandra compare with other approaches?

Menopausal symptoms, weakness, fatigue and abnormal liver tests have many causes. Evidence-based menopause care, progressive resistance exercise, adequate protein, medication review and medical evaluation answer different problems.

Ashwagandha, rhodiola, ginseng and schisandra are not a shared potency class. No strong head-to-head evidence identifies a universally best adaptogen, and milligrams across extracts cannot be compared directly.

What do public communities add?

Public discussions surface questions about stimulation, sleep, taste, cycling and stacking. They cannot authenticate species, quantify interaction risk or isolate schisandra from other changes. Anecdotes are not used here to set a dose or efficacy estimate.

Common questions

Are S. chinensis and S. sphenanthera the same?

No. They are related species. The efficacy trials highlighted here used S. chinensis; the strongest tacrolimus interaction evidence used S. sphenanthera. [2], [3], [5], [6]

Does schisandra help menopause symptoms?

One small BMO-30 trial reported a better composite symptom score and selected vasomotor signals. It needs replication and does not establish hormonal normalization. [2]

Does it build muscle?

One 12-week study with walking found greater knee-extension strength but no increase in muscle mass. It is not a substitute for progressive exercise or clinical assessment. [3]

Is schisandra proven for liver health?

No. Much of the evidence is preclinical, and a cited human trial combined schisandra with sesamin. Liver-enzyme changes do not prove treatment. [7]

Can I take it with tacrolimus?

Only under the transplant team's direction. S. sphenanthera products markedly increased tacrolimus exposure in human studies. [5], [6]

Can it interact with other medicines?

Yes, potentially through CYP enzymes and P-glycoprotein. Have a pharmacist review the exact product and full medicine list, especially for narrow-therapeutic-index drugs. [4]

Can it be used during pregnancy or breastfeeding?

Adequate safety evidence is lacking. Avoid self-directed use and seek professional guidance.

Is whole berry equivalent to a standardized extract?

No. Species, plant part, solvent, ratio and lignan profile can differ. Match evidence to the studied preparation.

Glossary

Terms used in this guide.

Lignans

A varied family of plant compounds; schisandra species contain characteristic dibenzocyclooctadiene lignans.

P-glycoprotein

A transport protein that moves many substances across cell membranes and can affect medicine exposure.

CYP3A

A family of enzymes involved in metabolism of many medicines, including tacrolimus.

AUC

Area under the concentration-time curve, a measure of total drug exposure over a defined period.

Titration

Changing an amount in planned steps. The selected efficacy trials do not establish general schisandra titration.

Preclinical

Research outside trials in people, such as cell or animal experiments.

How this guide was researched

This draft used Health Canada's 2025 cognitive-function product monograph, current MSK clinical guidance, FDA supplement guidance and primary records behind each numeric row. Searches covered species, fruit identity, menopause, muscle, liver markers, CYP and P-glycoprotein transport, and tacrolimus.

Corrections to the legacy manuscript include removing a generic 250–500 mg extract range, separating S. chinensis from S. sphenanthera, retaining null muscle-mass outcomes, identifying combination liver evidence and elevating the tacrolimus interaction. Evidence was refreshed October 9, 2026.

How this guide was made

The source ledger stores species, preparation, amount, frequency, duration, outcomes and limitations. Primary studies support trial-specific numbers; official and clinical sources frame safety and regulation. Draft status means scientific, French-parity, asset and rendered-page review remain separate gates.

Sources

Related guides